IF 2.8 3区医学

Eye Pub Date : 2025-02-19 DOI: 10.1038/s41433-025-03692-7

Laurent Kodjikian, Lilianne Duarte, Pankaj Singh, Maged Habib, Victor Gonzalez

{"title":"What have we learned from a decade treating patients with diabetic macular oedema with 0.19 mg fluocinolone acetonide intravitreal implant?","authors":"Laurent Kodjikian, Lilianne Duarte, Pankaj Singh, Maged Habib, Victor Gonzalez","doi":"10.1038/s41433-025-03692-7","DOIUrl":"https://doi.org/10.1038/s41433-025-03692-7","url":null,"abstract":"Diabetic macular oedema [DMO] is a prevalent and sight-threatening condition among diabetic patients, which can cause irreversible blindness. Since angiogenesis and inflammation are two key elements in the etiopathogenesis of DMO, intravitreal injections of vascular endothelial growth factor inhibitors [anti-VEGF] and sustained released intravitreal corticosteroid implants are currently considered as treatments of choice. The introduction, 10 years ago, of the 0.19 mg fluocinolone acetonide [FAc] implant for treating eyes with vision impairment associated with recurrent and persistent DMO represented an important advance. Since then, two randomized-control trials and many real-world studies have shown its good efficacy/safety profile and the replicability of its treatment regimen. The FAc implant is, in general terms well tolerated, although it is associated with intraocular pressure-[IOP] and cataract-related adverse events [AEs]. Most IOP-related AEs are effectively controlled with ocular-hypotensive therapies. The objective of this paper is to review the role of FAc implant in the treatment of DMO over the 10 years since its launch, as well as its impact on clinical practice outcomes.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aflibercept 2 mg biosimilars—will they lead the Anti-VEGF biosimilar world globally afliberept 2 mg生物仿制药将引领全球抗vegf生物仿制药世界吗？

IF 2.8 3区医学

Eye Pub Date : 2025-02-19 DOI: 10.1038/s41433-025-03732-2

Ashish Sharma, Se Joon Woo, Christopher Seungkyu Lee, Nilesh Kumar, Nikulaa Parachuri, Francesco Bandello, Anat Loewenstein, Baruch D. Kuppermann

引用次数: 0

Correction: Features of intermediate and late dry age-related macular degeneration on adaptive optics ophthalmoscopy: Pinnacle Study Report 8 更正：中期和晚期干性老年性黄斑变性在自适应光学视网膜上的特征：Pinnacle 研究报告 8。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03696-3

Ahmed M. Hagag, Christopher Holmes, Ahmer Raza, Sophie Riedl, Philipp Anders, Rebecca Kaye, Toby Prevost, Lars G. Fritsche, Daniel Rueckert, Hrvoje Bogunović, Hendrick P. N. Scholl, Ursula Schmidt-Erfurth, Andrew J. Lotery, Sobha Sivaprasad

引用次数: 0

Comparative models of uveitis. 葡萄膜炎的比较模型。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03693-6

Olivia S Knutson, Soyoung Choi, Simon Williams, Virginia L Calder

引用次数: 0

Late progressive atrophy in rubella retinopathy. 风疹视网膜病变的晚期进行性萎缩。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-024-03555-7

Shahanaz B Ahmed, Peter Charbel Issa

引用次数: 0

AI for glaucoma, Are we reporting well? a systematic literature review of DECIDE-AI checklist adherence 青光眼人工晶体植入术，我们的报告做得好吗？DECIDE-AI 检查表依从性系统文献综述。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03678-5

Benedict Leonard-Hawkhead, Bethany E. Higgins, David Wright, Augusto Azuara-Blanco

{"title":"AI for glaucoma, Are we reporting well? a systematic literature review of DECIDE-AI checklist adherence","authors":"Benedict Leonard-Hawkhead, Bethany E. Higgins, David Wright, Augusto Azuara-Blanco","doi":"10.1038/s41433-025-03678-5","DOIUrl":"10.1038/s41433-025-03678-5","url":null,"abstract":"This systematic literature review examines the quality of early clinical evaluation of artificial intelligence (AI) decision support systems (DSS) reported in glaucoma care. Artificial Intelligence applications within glaucoma care are increasing within the literature. For such DSS, there needs to be standardised reporting to enable faster clinical adaptation. In May 2022, a checklist to facilitate reporting of early AI studies (DECIDE-AI) was published and adopted by the EQUATOR network. The Cochrane Library, Embase, Ovid MEDLINE, PubMed, SCOPUS, and Web of Science Core Collection were searched for studies published between January 2020 and May 2023 that reported clinical evaluation of DSS for the diagnosis of glaucoma or for identifying the progression of glaucoma driven by AI. PRISMA guidelines were followed (PROSPERO registration: CRD42023431343). Study details were extracted and were reviewed against the DECIDE-AI checklist. The AI-Specific Score, Generic-Item Score, and DECIDE-AI Score were generated. A total of 1,552 records were screened, with 19 studies included within the review. All studies discussed an early clinical evaluation of AI use within glaucoma care, as defined by the a priori study protocol. Overall, the DECIDE-AI adherence score was low, with authors under reporting the AI specific items (30.3%), whilst adhering well to the generic reporting items (84.7%). Overall, reporting of important aspects of AI studies was suboptimal. Encouraging editors and authors to incorporate the checklist will enhance standardised reporting, bolstering the evidence base for integrating AI DSS into glaucoma care workflows, thus help improving patient care and outcomes.","PeriodicalId":12125,"journal":{"name":"Eye","volume":"39 6","pages":"1070-1080"},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41433-025-03678-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood omega-3 biomarkers, diabetic retinopathy and retinal vessel status in patients with type 1 diabetes. 1型糖尿病患者的血液omega-3生物标志物、糖尿病视网膜病变和视网膜血管状态

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03705-5

Aleix Sala-Vila, Irene Vinagre, Montserrat Cofán, Iolanda Lázaro, Anibal Alé-Chilet, Marina Barraso, Teresa Hernandez, William S Harris, Javier Zarranz-Ventura, Emilio Ortega

{"title":"Blood omega-3 biomarkers, diabetic retinopathy and retinal vessel status in patients with type 1 diabetes.","authors":"Aleix Sala-Vila, Irene Vinagre, Montserrat Cofán, Iolanda Lázaro, Anibal Alé-Chilet, Marina Barraso, Teresa Hernandez, William S Harris, Javier Zarranz-Ventura, Emilio Ortega","doi":"10.1038/s41433-025-03705-5","DOIUrl":"https://doi.org/10.1038/s41433-025-03705-5","url":null,"abstract":"Background/objectives: Clinical research on dietary omega-3 fatty acids and retinal health in type 1 diabetes (T1D) is scarce. In patients with T1D, we examined the associations between blood biomarkers of marine omega-3 (which reflect their dietary intake) and prevalent diabetic retinopathy (DR), and retinal microvascular data obtained through optical coherence tomography angiography (OCTA).Subjects/methods: Exploratory, cross-sectional sub-study of a prospective, consecutive, large-scale OCTA study conducted in a longitudinal cohort (ClinicalTrials.gov NCT03422965). We used baseline data from 188 consecutive patients with T1D and 88 controls. We determined blood omega-3 biomarkers (eicosapentaenoic [EPA], docosapentaenoic [DPA] and docosahexaenoic [DHA] acids) by gas-chromatography. Ocular data included DR grading, and 6 × 6 mm OCTA scans to obtain macular vessel density and perfusion density, and foveal avascular zone area, perimeter, and circularity.Results: Patients with T1D, regardless of DR stage, showed significantly lower blood levels of EPA, DHA, DHA, and EPA + DHA than non-diabetic controls (P < 0.001, all cases). In multivariate models in patients with T1D, higher EPA was associated with a lower prevalence of DR (P = 0.044); and increasing proportions of DPA, DHA, EPA + DHA, and total marine omega-3 fatty acids related to a higher vessel and perfusion densities in the macula (P values from 0.014 to 0.050).Conclusions: In patients with T1D, higher blood omega-3 status related to lower DR grades and preserved retinal perfusion. Our results, which are consistent with the current model of the pathogenesis of DR and data from experimental models, add to the notion of marine-derived omega-3 fatty acids as a healthy fat.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

I see blue. 我看到了蓝色。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03717-1

Shahzaib Rehan, Mario Saldanha

引用次数: 0

Iris melanoma in an Asian Indian with multifocal iris nevi. 一名患有多灶性虹膜痣的亚裔印度人的虹膜黑色素瘤。

IF 2.8 3区医学

Eye Pub Date : 2025-02-18 DOI: 10.1038/s41433-025-03709-1

Vijitha S Vempuluru, Swathi Kaliki

引用次数: 0

Management of extensive ocular surface neoplasia. 广泛眼表肿瘤的处理。